Clinical trials · Riverside–San Bernardino, CA
Cancer clinical trials in Riverside–San Bernardino
We’re tracking 943 recruiting cancer studies with a site in or near Riverside–San Bernardino — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT05984589Recruiting
Personal health coaching for colorectal cancer survivors
This study tests a personalized health coaching program to help colorectal cancer survivors improve their lifestyle habits, such as diet and physical activity, which may improve their health and well-being.
Los Angeles, CaliforniaAges 18 years+ - NCT07192432RecruitingPhase 1/Phase 2
Gene therapy for HER2-positive cancer
This trial tests a new gene therapy for people with HER2-positive cancer. It is for two groups: those with advanced cancer that has worsened after treatment, and those with early-stage cancer at high risk of coming back. The goal is to see if the therapy can safely help shrink tumors or prevent return.
Los Angeles, CaliforniaAges 18 years+ - NCT07719361RecruitingPhase 1
New drug for advanced, treatment-resistant prostate cancer
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
Los Angeles, CaliforniaAges 18 years+ - NCT04333706RecruitingPhase 1/Phase 2
Sarilumab plus capecitabine for certain breast cancers
This trial studies whether adding sarilumab to capecitabine can shrink or control metastatic or high-risk breast cancer that lacks HER2 and is either triple-negative or hormone-resistant. It aims to find a safe dose first, then look at how well the treatment works compared with historical results.
Los Angeles, CaliforniaAges 18–99 - NCT07383506RecruitingPhase 1
Study of a targeted pill for PIK3CA-mutated advanced cancers
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT06888102RecruitingEarly Phase 1
Epigenetic therapy before prostate surgery
This trial tests a short course of 'epigenetic therapy' (drugs that change how genes work) given before prostate removal surgery. The goal is to see if it can improve treatment effects and help shrink or control the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT07558733RecruitingPhase 1/Phase 2
New drug combinations for advanced hormone-receptor positive breast cancer
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT04364503Enrolling by invitation
Study that analyzes de-identified patient samples and records
This trial checks how well patient samples and health records can be analyzed when names are removed (“de-identified”) and privacy rules are followed. You might be included if you agree in writing and your sample data can be used for this research and/or your doctor requests it.
Los Angeles, CaliforniaAges Any age - NCT07339085Recruiting
Advanced MRI for brain tumor recurrence or radiation damage
This study uses advanced MRI scans to better tell the difference between a returning brain tumor and radiation injury. It may help guide your treatment decisions.
Los Angeles, CaliforniaAges 18 years+ - NCT06121180RecruitingPhase 2
Cemiplimab plus ziv-aflibercept for metastatic uveal melanoma
This trial tests two drugs, cemiplimab and ziv-aflibercept, together for people whose uveal melanoma has spread. It may be an option if previous treatments have stopped working or you haven't had treatment yet.
Los Angeles, CaliforniaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
Los Angeles, CaliforniaAges 18 years+ - NCT06880549RecruitingPhase 1
mRNA cancer vaccines alone or with other drugs for solid tumors
This study tests two experimental mRNA vaccines (mRNA-4106 and mRNA-4200) given either alone or together with other cancer treatments. The goal is to see if they are safe and work against advanced or metastatic solid tumors like melanoma, lung, liver, and colon cancer. Participation requires that you have tried or refused all standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04453072Recruiting
iPhone weight-loss app for teens and young adults after transplant
This study tests whether an iPhone weight-management app can help adolescents and young adults lose weight after a stem cell transplant. If you qualify, you’ll use the app and the team will track changes in weight.
Los Angeles, CaliforniaAges 13–30 - NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06084234RecruitingPhase 4
National liver cancer screening trial
This trial is testing a new way to screen for liver cancer in people with cirrhosis or chronic hepatitis B. It aims to find cancer earlier so it can be treated more effectively.
Los Angeles, CaliforniaAges 18–85 - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Los Angeles, CaliforniaAges 18 years+ - NCT06898450RecruitingPhase 1/Phase 2
Study of new drug NDI-219216 for advanced solid tumors
This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18–99 - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Los Angeles, CaliforniaAges 18 years+ - NCT05417594RecruitingPhase 1/Phase 2
Targeted drug study for advanced cancers with genetic changes
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
Los Angeles, CaliforniaAges 18–130 - NCT06126276RecruitingPhase 2
Testing neratinib with or without palbociclib for HER2+ solid tumors
This trial tests two targeted drugs—neratinib alone or with palbociclib—for people with HER2-positive solid tumors (other than breast cancer) that have returned or not gone away. The goal is to see if blocking HER2 and CDK4/6 can shrink or slow the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06810778RecruitingPhase 1/Phase 2
Duvelisib plus venetoclax for relapsed PTCL
This study tests two oral drugs—duvelisib and venetoclax—to see if together they can help people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07323641RecruitingPhase 2
Telisotuzumab Vedotin and Osimertinib for Advanced Lung Cancer
This trial tests a combination of two drugs—telisotuzumab vedotin and osimertinib—for people with a specific type of advanced non-small cell lung cancer that has stopped responding to osimertinib alone. The goal is to see if adding the second drug can help control the cancer.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Cancer trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting cancer studies listed above.
- START Los Angeles · 4 studies
- UCLA Jonsson Comprehensive Cancer Center · 4 studies
- USC Norris Comprehensive Cancer Center · 4 studies
- Cedars-Sinai Medical Center · 3 studies
- University of Southern California · 3 studies
- The Angeles Clinic and Research Institute · 2 studies
- Valkyrie Clinical Trials · 2 studies
- Cedars-Sinai Cancer at SOCC
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in California.
Common questions
- Are there cancer clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 943 recruiting cancer studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.